Aura Biosciences, Inc.

NasdaqGM:AURA Stock Report

Market Cap: US$383.3m

Aura Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:AURA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 May 25SellUS$7,823Anthony GibneyIndividual1,519US$5.15
16 May 25BuyUS$245,000Anthony GibneyIndividual50,000US$4.90
16 May 25BuyUS$98,000David JohnsonIndividual20,000US$4.90
16 Apr 25SellUS$4,925Amy ElazzouziIndividual897US$5.49
16 Apr 25SellUS$39,319Conor KilroyIndividual7,162US$5.49
18 Feb 25SellUS$16,670Mark PlavsicIndividual2,151US$7.75
18 Feb 25SellUS$10,881Amy ElazzouziIndividual1,404US$7.75
18 Feb 25SellUS$19,639Jill HopkinsIndividual2,534US$7.75
18 Feb 25SellUS$156,796Elisabet de los PinosIndividual20,221US$7.75
21 Jan 25SellUS$122,381Elisabet de los PinosIndividual15,955US$7.67
21 Jan 25SellUS$7,679Amy ElazzouziIndividual1,001US$7.67
18 Nov 24SellUS$110,663Jill HopkinsIndividual11,822US$9.36
29 Oct 24SellUS$5,938Amy ElazzouziIndividual553US$10.74
29 Oct 24SellUS$98,788Elisabet de los PinosIndividual9,200US$10.74
16 Oct 24SellUS$72,723Mark PlavsicIndividual7,383US$9.85

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AURA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders965,2481.55%
VC/PE Firms5,100,0008.21%
General Public8,403,37513.5%
Hedge Funds20,796,46133.5%
Institutions26,854,78943.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.2%.

Top Shareholders

Top 25 shareholders own 80.67% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.1%
Matrix Capital Management Company, LP
6,922,870US$42.7m0%12.42%
8.21%
Frazier Life Sciences Management, LP
5,100,000US$31.5m0%0.95%
7.86%
Adage Capital Management, L.P.
4,881,125US$30.1m0%0.05%
7.44%
Long Focus Capital Management LLC
4,619,582US$28.5m39.2%1.67%
7.04%
Suvretta Capital Management, LLC
4,372,884US$27.0m60.1%0.85%
4.99%
BlackRock, Inc.
3,102,524US$19.1m-12.4%no data
4.89%
Medicxi Ventures (UK) LLP
3,039,892US$18.8m0%2.58%
3.99%
The Vanguard Group, Inc.
2,477,502US$15.3m26.9%no data
3.77%
Franklin Resources, Inc.
2,340,250US$14.4m5.88%no data
3.41%
Nantahala Capital Management, LLC
2,117,697US$13.1m67.1%0.67%
2.82%
Lundbeckfonden BioCapital
1,750,108US$10.8m0%0.14%
2.41%
Levin Capital Strategies, L.P.
1,495,560US$9.2m9.91%0.85%
1.61%
Samsara BioCapital LLC
1,000,000US$6.2m0%0.74%
1.5%
Geode Capital Management, LLC
929,974US$5.7m-9.32%no data
1.43%
UBS Asset Management AG
891,028US$5.5m18.3%no data
1.38%
State Street Global Advisors, Inc.
856,186US$5.3m7.97%no data
1.07%
Regency Capital Management Inc.
665,881US$4.1m-11.2%2.06%
0.96%
Acorn Bioventures
595,744US$3.7m0.89%2.0%
0.92%
The B Group, Inc.
572,576US$3.5m21.2%2.71%
0.83%
Decheng Capital LLC
515,555US$3.2m0%0.58%
0.81%
T. Rowe Price Group, Inc.
504,828US$3.1m-2.88%no data
0.73%
Dimensional Fund Advisors LP
456,157US$2.8m12.4%no data
0.6%
Northern Trust Global Investments
370,472US$2.3m-1.08%no data
0.51%
David Johnson
316,167US$2.0m10.7%no data
0.35%
Elisabet de los Pinos
215,155US$1.3m0.47%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/30 23:11
End of Day Share Price 2025/09/30 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aura Biosciences, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan WollebenCitizens JMP Securities, LLC
Liisa BaykoEvercore ISI
Edward WhiteH.C. Wainwright & Co.